INT178174

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 2004
Last Reported 2010
Negated 3
Speculated 1
Reported most in Body
Documents 78
Total Number 79
Disease Relevance 56.83
Pain Relevance 8.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Tnfsf10)
Anatomy Link Frequency
plasma 4
cardiomyocytes 4
cleavage 2
bladder 2
articular 2
Tnfsf10 (Mus musculus)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 927 99.86 Very High Very High Very High
cytokine 757 99.32 Very High Very High Very High
Inflammation 991 99.12 Very High Very High Very High
fortral 56 98.42 Very High Very High Very High
agonist 45 98.12 Very High Very High Very High
chemokine 160 97.52 Very High Very High Very High
Arthritis 930 97.44 Very High Very High Very High
Angina 44 97.04 Very High Very High Very High
antagonist 37 90.16 High High
metalloproteinase 111 87.36 High High
Disease Link Frequency Relevance Heat
Apoptosis 1652 100.00 Very High Very High Very High
Rheumatoid Arthritis 927 99.86 Very High Very High Very High
Death 429 99.84 Very High Very High Very High
Myocardial Infarction 1166 99.72 Very High Very High Very High
Bladder Cancer 53 99.40 Very High Very High Very High
Necrosis 146 99.14 Very High Very High Very High
INFLAMMATION 784 99.12 Very High Very High Very High
Cancer 1597 98.96 Very High Very High Very High
Coronary Artery Disease 70 98.68 Very High Very High Very High
Toxicity 144 98.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found an inverse correlation between the serum levels of TRAIL, measured within 24 hours after admission, and both CK (R?
Gene_expression (levels) of TRAIL
1) Confidence 0.76 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.56 Pain Relevance 0
Fusion protein anti-MCSP:TRAIL was produced in CHO-K1 cells using previously described methods [14,16].
Gene_expression (produced) of TRAIL
2) Confidence 0.71 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.05 Pain Relevance 0
TRAIL serum levels show an inverse correlation with biochemical predictors of cardiovascular events
Gene_expression (levels) of TRAIL
3) Confidence 0.66 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.58 Pain Relevance 0
Decreased TRAIL serum levels represent a negative prognostic factor at 12 months of follow-up in both univariable and multivariable analyses
Gene_expression (levels) of TRAIL
4) Confidence 0.66 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.61 Pain Relevance 0
Our findings confirm and extend previous studies, which showed that the serum levels of TRAIL are decreased in patients affected by coronary artery disease (including angina pectoris and AMI) [5], [6].
Gene_expression (levels) of TRAIL in coronary artery associated with angina, coronary artery disease and myocardial infarction
5) Confidence 0.66 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 1.08 Pain Relevance 0.10
TRAIL is primarily expressed as a type II transmembrane protein in which the carboxyl terminus of the receptor-binding domain protrudes extracellularly.
Gene_expression (expressed) of TRAIL
6) Confidence 0.64 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 0.38 Pain Relevance 0
Despite their resistance to TRAIL (recombinant TRAIL protein or Ad-stTRAIL), U373-MG and ACBRI371 cells expressed TRAIL receptors DR4 and DR5 (data not shown).
Gene_expression (expressed) of TRAIL
7) Confidence 0.64 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 0.90 Pain Relevance 0
To develop a biologically active form of soluble TRAIL produced in mammalian cells, we manipulated the apoptosis-inducing moiety of TRAIL (amino acids 114–281) to be secreted through fusion with a secretion signal sequence.
Gene_expression (produced) of TRAIL associated with apoptosis
8) Confidence 0.64 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 1.13 Pain Relevance 0
Rimcazole did not upregulate TRAIL-R1 or TRAIL-R2 expression (data not shown), but augmented the activation of initiator caspase-8 and initiator caspase-9 upon anti-MCSP:TRAIL treatment (Additional file 3, Figure S2A and B, respectively).
Gene_expression (expression) of TRAIL
9) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.62 Pain Relevance 0.18
Construction of fusion protein anti-MCSP:TRAIL
Gene_expression (Construction) of TRAIL
10) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.05 Pain Relevance 0
Rimcazole did not upregulate TRAIL-R1 or TRAIL-R2 expression (data not shown), but augmented the activation of initiator caspase-8 and initiator caspase-9 upon anti-MCSP:TRAIL treatment (Additional file 3, Figure S2A and B, respectively).
Gene_expression (expression) of TRAIL
11) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.62 Pain Relevance 0.18
Indeed A375M cells, that solely express TRAIL-R2 at the cell surface are sensitive to treatment with anti-MCSP:TRAIL (Figure 1B, Additional file 1, Figure S1E), indicating that anti-MCSP:TRAIL can potently activate TRAIL-R2 signaling in MCSP-positive melanoma cells.
Gene_expression (express) of TRAIL associated with melanoma
12) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.47 Pain Relevance 0
Indeed, although anti-MCSP:TRAIL strongly bound to MCSP on normal human melanocytes (Additional file 1, Figure S1D), no apoptosis was induced in melanocytes even when treatment was performed with 4 ?
Neg (no) Gene_expression (although) of TRAIL in melanocytes associated with apoptosis
13) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.94 Pain Relevance 0
-R1 agonist (+)pentazocine did not abrogate synergy, suggesting that rimcazole synergizes with anti-MCSP:TRAIL activity via ?
Gene_expression (activity) of TRAIL associated with fortral and agonist
14) Confidence 0.62 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.58 Pain Relevance 0.19
Although the cellular source of serum TRAIL has not been clearly established, it is important to point out that TRAIL is expressed as a type-II TNF family transmembrane protein, but its extracellular domain can be released as a soluble cytokine [7].
Gene_expression (expressed) of TRAIL associated with cytokine
15) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.78 Pain Relevance 0.13
In the next group of analyses, the serum levels of TRAIL were evaluated with respect to important biochemical markers of cardiovascular related death and HF.
Gene_expression (levels) of TRAIL associated with myocardial infarction and death
16) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.60 Pain Relevance 0
In particular, at discharge (approximately 5–6 days after admission), the serum levels of TRAIL were already significantly increased, compared to the acute phase, but still significantly (p<0.01) lower with respect to normal controls (Figure 1).
Gene_expression (levels) of TRAIL
17) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.51 Pain Relevance 0
Serum levels of TRAIL were significantly decreased in patients with AMI at baseline (within 24 hours from admission), compared with healthy controls, and showed a significant inverse correlation with a series of negative prognostic markers, such as CK, CK-MB and BNP.
Gene_expression (levels) of TRAIL associated with myocardial infarction
18) Confidence 0.59 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2637972 Disease Relevance 0.81 Pain Relevance 0.04
Interestingly, one study has reported enhanced expression of transmembrane TRAIL on the cell surface of circulating CD3+ and CD14+ cells after AMI and has documented the expression of two of the four transmembrane receptors for TRAIL, TRAIL-R1 and TRAIL-R2, in human cardiomyocytes [3].
Gene_expression (expression) of TRAIL in cardiomyocytes associated with myocardial infarction
19) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.91 Pain Relevance 0.11
Interestingly, one study has reported enhanced expression of transmembrane TRAIL on the cell surface of circulating CD3+ and CD14+ cells after AMI and has documented the expression of two of the four transmembrane receptors for TRAIL, TRAIL-R1 and TRAIL-R2, in human cardiomyocytes [3].
Gene_expression (expression) of TRAIL-R1 in cardiomyocytes associated with myocardial infarction
20) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.91 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox